BUZZ-Sarepta to release 3-year data for muscle dystrophy gene therapy; shares rise** Shares of genetic medicine maker Sarepta Therapeutics SRPT.O rise 6.4% to $22.49 premarket
** Co says it will present three‑year results from its EMBARK trial of Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD) — a muscle‑wasting disease
** Elevidys is designed to deliver a shortened dystrophin gene to help slow progressive muscle decline, co says
** SRPT says results will be shared via webcast on January 26 at 8:30 a.m. ET
** Trial tested Elevidys against placebo in boys aged between 4 and 7 years who had not yet lost the ability to walk due to DMD, co says
** Shares fell ~82% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments